MedTrace Logo

Chrysin Bioavailability and Safety

NCT07066839 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-07-15

No results posted yet for this study

Summary

This study seeks to evaluate and compare the pharmacokinetics of a micellar chrysin formulation (LipoMicel Chrysin) with that of a non-micellar chrysin formulation as well as a standard/unformulated chrysin supplement. The study also seeks to determine the short-term effects and safety of daily oral supplementation of LipoMicel Chrysin in healthy adult volunteers over a 30-day study period.

Conditions

  • Bioavailability and Pharmacokinetics
  • Safety After Oral Intake

Interventions

DIETARY_SUPPLEMENT

LipoMicel Chrysin

A maximum single oral dose of 1000 mg chrysin

DIETARY_SUPPLEMENT

Non-Micellar Chrysin

A maximum single oral dose of 1000 mg chrysin

DIETARY_SUPPLEMENT

Standard/Unformulated Chrysin

A maximum single oral dose of 1000 mg chrysin

Sponsors & Collaborators

  • Isura

    lead OTHER

Principal Investigators

  • Julia Solnier, PhD · Isura

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-05
Primary Completion
2025-02-21
Completion
2025-04-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07066839 on ClinicalTrials.gov